The Idea
Our mission is to develop innovative treatments for diseases characterized by disproportional activation of inflammation, leveraging the body’s natural defense system as a template.
The Need
Inflammatory diseases are major threats to human health and are associated with significant mortality as well as costs for society. According to the World Health Organization (WHO) three out of five people die because of chronic inflammatory diseases including diseases such as stroke, chronic respiratory diseases, heart disorders, obesity, cancer, and diabetes.
"With its unique mode of action, TIM-03 stands out as a promising drug candidate, addressing the significant unmet need for effective treatments across a wide range of inflammatory diseases."
Helene Hartman, CEO Transient Pharma AB
News
Transient Pharma AB attracts SEK 16 million in investments through an oversubscribed new share issue.
Lund, Sweden, 27 June 2024 - Transient Pharma AB has secured 16 million SEK in funding from SmiLe Inject Capital AB and private investors to advance the pre-clinical development of their novel drug…
Transient Pharma AB Joins SmiLe as New Incubator Company
Lund, Sweden – SmiLe is very pleased to announce the addition of Transient Pharma AB to our incubator program. Transient Pharma is dedicated to the development of innovative systemic…
A step closer to treatment for severe bacterial infections and sepsis
The development of a new treatment strategy for bacterial infections and sepsis is being led by researchers at Lund University. In a study the researchers demonstrate how they, by mimicking a…
Upcoming Events
Meet us at BIO-Europe in Stockholm!
4 - 6 November, 2024
BIO-Europe, Europe’s leading partnering event, provides an opportunity to connect with potential partners and investors spanning the global life science ecosystem. We plan to attend, and we are happy to meet you there.
Scientific Publications
Explore our publications on Thrombin-derived C-terminal Peptides (TCPs), their mode of action and efficacy in vitro and in vivo.
